Is Roxithromycin compatible with breastfeeding? Do we have alternatives for Roxithromycin?

Roxithromycin

July 20, 2017 (Very Low Risk)

Less than 0.05% of the maternal dose of roxithromycin is excreted in milk (AEMPS 2002, Puri 1987).

Early exposure to macrolides (especially erythromycin, see specific information) has been linked to the occurrence of hypertrophic pyloric stenosis (Goldstein 2009, Chin 2001), including through breast milk, so it may be prudent to avoid them during the first month of breastfeeding.

Be aware of false negative results of bacterial cultures obtained from febrile infants whose mothers are on antibiotics, as well as the possibility of gastroenteritis due to altered intestinal flora (Ito 1993).


See below the information of this related product:

Alternatives

We do not have alternatives for Roxithromycin since it is relatively safe.

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Writings

  • روكسيثروميسين (Arabic)
  • Рокситромицин (Cyrillic)
  • 罗红霉素 (Chinese)
  • ロキシスロマイシン (Japanese)
  • C41H76N2O15 (Molecular formula)
  • RU-28965 (Experimental code/s)

Drug trade names

References

  1. Sanofi. Roxithromycin. Drug Summary. 2012 Full text (in our servers)
  2. Amir LH, Pirotta MV, Raval M. Breastfeeding--evidence based guidelines for the use of medicines. Aust Fam Physician. 2011Abstract Full text (link to original source) Full text (in our servers)
  3. Goldstein LH, Berlin M, Tsur L, Bortnik O, Binyamini L, Berkovitch M. The safety of macrolides during lactation. Breastfeed Med. 2009Abstract
  4. AEMPS. Roxitromicina. Ficha técnica. 2002 Full text (in our servers)
  5. Chin KG, McPherson CE 3rd, Hoffman M, Kuchta A, Mactal-Haaf C. Use of anti-infective agents during lactation: Part 2--Aminoglycosides, macrolides, quinolones, sulfonamides, trimethoprim, tetracyclines, chloramphenicol, clindamycin, and metronidazole. J Hum Lact. 2001Abstract
  6. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993Abstract
  7. Periti P, Mazzei T, Mini E, Novelli A. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). Clin Pharmacokinet. 1989Abstract
  8. Puri SK, Lassman HB. Roxithromycin: a pharmacokinetic review of a macrolide. J Antimicrob Chemother. 1987Abstract